Supplement

You have full text access to this OnlineOpen article

Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference†‡

  1. Steven E. Come MD1,§,¶,*,
  2. Aman U. Buzdar MD2,‖,
  3. James N. Ingle MD3,††,
  4. Stephen R. D. Johnston MD, PhD, FRCP4,‡‡,
  5. Angela M. Brodie PhD5,§§,
  6. R. Charles Coombes MD6,¶¶,
  7. William R. Miller MD, PhD, DSc7,‖‖,
  8. Kathleen I. Pritchard MD8,†††,
  9. Eric P. Winer MD9,‡‡‡,
  10. Jo Anne Zujewski MD10,
  11. Paul E. Goss MD, PhD, FRCPC, FRCP11,§§§

Article first published online: 10 DEC 2007

DOI: 10.1002/cncr.23194

Issue

Cancer

Cancer

Volume 112, Issue S3, pages 673–678, 1 February 2008

Additional Information

How to Cite

Come, S. E., Buzdar, A. U., Ingle, J. N., Johnston, S. R. D., Brodie, A. M., Coombes, R. C., Miller, W. R., Pritchard, K. I., Winer, E. P., Zujewski, J. A. and Goss, P. E. (2008), Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference. Cancer, 112: 673–678. doi: 10.1002/cncr.23194

Author Information

  1. 1

    Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts

  2. 2

    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Division of Medical Oncology, The Mayo Clinic, Rochester, Minnesota

  4. 4

    Department of Medicine, Royal Marsden Hospital, London, United Kingdom

  5. 5

    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland

  6. 6

    Department of Medicine, Breast Unit, Imperial College School of Medicine, London, United Kingdom

  7. 7

    Breast Research Group, University of Edinburgh, Edinburgh, United Kingdom

  8. 8

    Clinical Trials and Epidemiology, University of Toronto at Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada

  9. 9

    Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts

  10. 10

    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland

  11. 11

    Breast Cancer Research, Massachusetts General Cancer Center, Boston, Massachusetts

  1. §

    Dr. Come has acted as a consultant and member of the Speakers' Bureau and has received research support from AstraZeneca. He has also acted as a member of the Speakers' Bureau for Novartis and Pfizer.

  2. Fax: (617) 667-9919.

  3. ‖

    Dr. Buzdar has received research funding from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, Pfizer, and Taiho.

  4. ††

    Dr. Ingle has acted as a consultant for Novartis.

  5. ‡‡

    Dr. Johnston has received research funding from AstraZeneca and GlaxoSmithKline, and has been a member of the Speakers' Bureau for GlaxoSmithKline.

  6. §§

    Dr. Brodie is a member of the Advisory Board for AstraZeneca and Pfizer, and has received research support from AstraZeneca and Novartis.

  7. ¶¶

    Dr. Coombes has received honoraria from AstraZeneca and has received honoraria and research support from Pfizer.

  8. ‖‖

    Dr. Miller has received honoraria and is a member of the Speakers' Bureau for AstraZeneca, Novartis, and Pfizer.

  9. †††

    Dr. Pritchard has acted on the advisory committee and received honoraria from Aefera; received research funding from Amgen; acted on the advisory board, acted as a consultant, provided expert testimony, and received honoraria and research funding from AstraZeneca; acted as a consultant for Biomira; received research funding from Bristol-Myers Squibb; acted on the advisory committee, acted as a consultant, and received honoraria from Hoffmann-La Roche; received research funding from the National Cancer Institute of Canada; acted on the advisory board, acted as a consultant, and received honoraria and research funding from Novartis; acted on the advisory board, acted as a consultant, and received research funding from Ortho-Biotech; acted on the advisory committee, acted as a consultant, and received honoraria and research funding from Pfizer; acted on the advisory committee, acted as a consultant, provided expert testimony, and received honoraria and research funding from Sanofi-Aventis; and acted on the advisory committee, acted as a consultant, and received honoraria and research funding from YM Biosciences.

  10. ‡‡‡

    Dr. Winer is a member of the advisory board for AstraZeneca and Pfizer.

  11. §§§

    Dr. Goss is a member of the advisory board and Speakers' Bureau for AstraZeneca, GlaxoSmithKline, Pfizer, and Novartis.

*Breast Cancer Program, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Room CC-913, Boston, MA 02215

  1. †

    The symposium and educational proceedings publications were supported by educational grants provided by AstraZeneca Pharmaceuticals, Pfizer Inc, and Novartis Pharmaceuticals. Program management and Continuing Medical Education Sponsorship were provided by InforMEDical Communications, Inc, Carlisle, Massachusetts

  2. ‡

    Presented at Endocrine and Targeted Manipulation of Breast Cancer: Proceedings of the Sixth Cambridge Conference, Cambridge, Massachusetts, April 30–May 1, 2007.

Publication History

  1. Issue published online: 18 JAN 2008
  2. Article first published online: 10 DEC 2007
  3. Manuscript Accepted: 11 OCT 2007
  4. Manuscript Revised: 8 OCT 2007
  5. Manuscript Received: 24 AUG 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (87K)

Keywords:

  • endocrine therapy;
  • breast cancer;
  • estrogen;
  • aromatase inhibitors;
  • tamoxifen

Abstract

The Sixth Cambridge Conference on Endocrine and Targeted Manipulation of Breast Cancer was convened in Cambridge, Massachusetts on April 30 and May 1, 2007. The purpose of this multidisciplinary meeting of leaders in clinical and basic research and patient treatment was to assess the most recent data in the field, articulate current best practices, and identify the next steps to advance both patient care and research. Topics included a review of data from major recent and ongoing trials of endocrine treatment in patients with early breast cancer and from studies combining endocrine therapy with other treatment. The current status of breast cancer prevention efforts was examined. Preclinical models of response and resistance, initial efforts to profile tumor response and resistance during endocrine therapy in patients, and new developments in pharmacogenomics were also highlighted. In this article, a synopsis of the key issues discussed, conclusions, and recommendations are summarized; these are presented at greater length in the individual articles and accompanying Open Discussions that comprise the full conference proceedings. In the 2 years since the Fifth Conference, we have gained valuable follow-up data from key trials in early breast cancer, which have helped to clarify both the efficacy and safety and tolerability of the available strategies for endocrine therapy. Observations using endocrine agents in combination with other treatment have been similarly extended. More detailed analysis of preclinical models has improved our understanding of resistance to endocrine therapy, and efforts to explore these and other mechanisms in the clinic are now underway. All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer. Cancer 2008. © 2007 American Cancer Society.

View Full Article (HTML) Get PDF (87K)